Investigating the effects of arginine methylation inhibitors on microdissected brain tumour biopsies maintained in a miniaturised perfusion system

Barry, Antonia; Samuel, Sabrina F.; Hosni, Ines; Moursi, Amr; Feugere, Lauric; Sennett, Christopher J.; Deepak, Srihari; Achawal, Shailendra; Rajaraman, Chittoor; Iles, Alexander; Wollenberg Valero, Katharina C.; Scott, Ian S.; Green, Vicky; Stead, Lucy F.; Greenman, John; Wade, Mark A.; Beltran-Alvarez, Pedro

Abstract

Arginine methylation is a post-translational modification that consists of the transfer of one or two methyl (CH3) groups to arginine residues in proteins. Several types of arginine methylation occur, namely monomethylation, symmetric dimethylation and asymmetric dimethylation, which are catalysed by different protein arginine methyltransferases (PRMTs). Inhibitors of PRMTs have recently entered clinical trials to target several types of cancer, including gliomas (NCT04089449). People with glioblastoma (GBM), the most aggressive form of brain tumour, are among those with the poorest quality of life and likelihood of survival of anyone diagnosed with cancer. There is currently a lack of (pre)clinical research on the possible application of PRMT inhibitors to target brain tumours. Here, we set out to investigate the effects of clinically-relevant PRMT inhibitors on GBM biopsies. We present a new, low-cost, easy to fabricate perfusion device that can maintain GBM tissue in a viable condition for at least eight days post-surgical resection. The miniaturised perfusion device enables the treatment of GBM tissue with PRMT inhibitors ex vivo, and we observed a two-fold increase in apoptosis in treated samples compared to parallel control experiments. Mechanistically, we show thousands of differentially expressed genes after treatment, and changes in the type of arginine methylation of the RNA binding protein FUS that are consistent with hundreds of differential gene splicing events. This is the first time that cross-talk between different types of arginine methylation has been observed in clinical samples after treatment with PRMT inhibitors.

Citation

Barry, A., Samuel, S. F., Hosni, I., Moursi, A., Feugere, L., Sennett, C. J., …Beltran-Alvarez, P. (2023). Investigating the effects of arginine methylation inhibitors on microdissected brain tumour biopsies maintained in a miniaturised perfusion system. Lab on a chip, 23(11), 2664-2682. https://doi.org/10.1039/d3lc00204g

• Journal Article Type: Article
• Acceptance Date: May 3, 2023
• Online Publication Date: May 3, 2023
• Publication Date: Jun 7, 2023
• Deposit Date: May 3, 2023
• Publicly Available Date: Jun 2, 2023
• Journal: Lab on a Chip
• Print ISSN: 1473-0197
• Electronic ISSN: 1473-0189
• Publisher: Royal Society of Chemistry
• Peer Reviewed: Peer Reviewed
• Volume: 23
• Issue: 11
• Pages: 2664-2682
• DOI: https://doi.org/10.1039/d3lc00204g
• Public URL: https://hull-repository.worktribe.com/output/4276367